TW202323522A - 用於調節基因體的方法及組合物 - Google Patents

用於調節基因體的方法及組合物

Info

Publication number
TW202323522A
TW202323522A TW111134204A TW111134204A TW202323522A TW 202323522 A TW202323522 A TW 202323522A TW 111134204 A TW111134204 A TW 111134204A TW 111134204 A TW111134204 A TW 111134204A TW 202323522 A TW202323522 A TW 202323522A
Authority
TW
Taiwan
Prior art keywords
domain
sequence
cas
genetically modified
modified polypeptide
Prior art date
Application number
TW111134204A
Other languages
English (en)
Chinese (zh)
Inventor
羅伯特 查爾斯 奧茲胡勒
安 海倫 巴斯摩爾
拉莫西諾 賽西莉亞 喬凡娜 賽爾維雅 寇特
蘭迪 蜜雪爾 寇特拉爾
安娜亞 雷
納薩尼珥 羅奎特
卡洛斯 桑切斯
巴雷特 伊森 史丹伯格
Original Assignee
美商旗艦先鋒創新有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商旗艦先鋒創新有限責任公司 filed Critical 美商旗艦先鋒創新有限責任公司
Publication of TW202323522A publication Critical patent/TW202323522A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111134204A 2021-09-08 2022-09-08 用於調節基因體的方法及組合物 TW202323522A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163241953P 2021-09-08 2021-09-08
US63/241,953 2021-09-08
US202263373444P 2022-08-24 2022-08-24
US63/373,444 2022-08-24
WOPCT/US22/76045 2022-09-07
PCT/US2022/076045 WO2023039424A2 (en) 2021-09-08 2022-09-07 Methods and compositions for modulating a genome

Publications (1)

Publication Number Publication Date
TW202323522A true TW202323522A (zh) 2023-06-16

Family

ID=85507644

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111134204A TW202323522A (zh) 2021-09-08 2022-09-08 用於調節基因體的方法及組合物

Country Status (10)

Country Link
US (5) US12024728B2 (cg-RX-API-DMAC7.html)
EP (1) EP4399292A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024533311A (cg-RX-API-DMAC7.html)
KR (1) KR20260037664A (cg-RX-API-DMAC7.html)
AU (1) AU2022343268A1 (cg-RX-API-DMAC7.html)
CA (1) CA3231677A1 (cg-RX-API-DMAC7.html)
IL (1) IL311225A (cg-RX-API-DMAC7.html)
MX (1) MX2024002927A (cg-RX-API-DMAC7.html)
TW (1) TW202323522A (cg-RX-API-DMAC7.html)
WO (1) WO2023039424A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019327449B2 (en) 2018-08-28 2026-04-09 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
IL296095A (en) 2020-03-04 2022-11-01 Flagship Pioneering Innovations Vi Llc Improved methods and compositions for genome modulation
BR112022017715A2 (pt) 2020-03-04 2022-11-16 Flagship Pioneering Innovations Vi Llc Métodos e composições para modular um genoma
EP4095246A1 (en) * 2021-05-27 2022-11-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel crispr grnas
CA3231712A1 (en) 2021-09-08 2023-03-16 Flagship Pioneering Innovations Vi, Llc Pah-modulating compositions and methods
KR20260037664A (ko) 2021-09-08 2026-03-18 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 게놈을 조절하기 위한 방법 및 조성물
IL312965A (en) * 2021-11-24 2024-07-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and their uses
EP4444362A4 (en) 2021-12-10 2026-04-01 Flagship Pioneering Innovations Vi Llc CFTR COMPOSITIONS AND MODULATION METHODS
JP2026525612A (ja) 2023-07-25 2026-07-31 フラッグシップ パイオニアリング イノベーションズ セブン,エルエルシー Casエンドヌクレアーゼ及び関連方法
KR20260044217A (ko) 2023-07-25 2026-04-01 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 Cas 엔도뉴클레아제 및 관련 방법
WO2025072331A1 (en) 2023-09-26 2025-04-03 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
IL327927A (en) * 2023-10-22 2026-06-01 Tessera Therapeutics Inc Lipid nanoparticles for delivery of therapeutic payloads to t cells
WO2025117877A2 (en) 2023-12-01 2025-06-05 Flagship Pioneering Innovations Vii, Llc Cas nucleases and related methods
WO2025194138A1 (en) * 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. St1cas9 compositions and methods for modulating a genome
WO2026015832A2 (en) * 2024-07-12 2026-01-15 Arbor Biotechnologies, Inc. Reverse transcriptases and gene editing systems comprising such
WO2026135182A1 (ko) * 2024-12-19 2026-06-25 주식회사 씨젠 돌연변이 m-mlv 역전사 효소

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
CA2196419C (en) 1994-08-20 2007-08-21 Yen Choo Improvements in or relating to binding proteins for recognition of dna
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US6699663B1 (en) 1995-12-14 2004-03-02 The General Hospital Corporation Molecular sequence of swine retrovirus
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
GB2338237B (en) 1997-02-18 2001-02-28 Actinova Ltd In vitro peptide or protein expression library
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6503717B2 (en) 1999-12-06 2003-01-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
EP1083231A1 (en) 1999-09-09 2001-03-14 Introgene B.V. Smooth muscle cell promoter and uses thereof
AU2001250774B2 (en) 2000-02-08 2005-01-27 Sangamo Biosciences, Inc. Cells expressing zinc finger proteins for drug discovery
AU2001263155A1 (en) 2000-05-16 2001-11-26 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
US6627424B1 (en) 2000-05-26 2003-09-30 Mj Bioworks, Inc. Nucleic acid modifying enzymes
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7169874B2 (en) 2001-11-02 2007-01-30 Bausch & Lomb Incorporated High refractive index polymeric siloxysilane compositions
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US7375234B2 (en) 2002-05-30 2008-05-20 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
EP1636343B1 (en) 2003-05-28 2013-08-21 The Johns-Hopkins University Synthetic mammalian retrotransposon gene
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
KR100437889B1 (ko) * 2003-08-26 2004-07-07 주식회사 인트론바이오테크놀로지 세망내피증 바이러스의 역전사 효소 및 이를 생산하는 방법
US7070941B2 (en) 2003-11-17 2006-07-04 Board Of Regents, The University Of Texas System Methods and compositions for tagging via azido substrates
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7253273B2 (en) 2004-04-08 2007-08-07 Sangamo Biosciences, Inc. Treatment of neuropathic pain with zinc finger proteins
ATE418346T1 (de) 2004-04-08 2009-01-15 Sangamo Biosciences Inc Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen
ES2547381T3 (es) 2004-04-09 2015-10-05 Monsanto Technology, Llc Composiciones y procedimientos de control de infestaciones de insectos en plantas
EP2397490B1 (en) 2004-07-16 2013-09-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Vaccine constructs and combinations of vaccines designed to improve the breadth of the immune response to diverse strains and clades of HIV
DE102004034461B4 (de) 2004-07-16 2008-02-07 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren
ES2716864T3 (es) 2007-06-06 2019-06-17 Monsanto Technology Llc Genes y usos para la mejora de plantas
JP2011512326A (ja) 2007-12-31 2011-04-21 ナノコア セラピューティクス,インコーポレイテッド 心不全の治療用のrna干渉
US8394604B2 (en) 2008-04-30 2013-03-12 Paul Xiang-Qin Liu Protein splicing using short terminal split inteins
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
EP2937418B1 (en) 2008-10-20 2017-10-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
GB0901593D0 (en) 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
JP5882064B2 (ja) 2009-03-04 2016-03-09 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 安定化された逆転写酵素融合タンパク質
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
AU2010325563B2 (en) 2009-11-27 2017-02-02 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
EP2500434A1 (en) 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
US8846883B2 (en) 2011-08-16 2014-09-30 University Of Southhampton Oligonucleotide ligation
PT2877490T (pt) 2012-06-27 2019-02-12 Univ Princeton Inteínas clivadas, conjugados e suas utilizações
CN102723640B (zh) 2012-07-09 2015-08-26 东莞中探探针有限公司 磁性连接器结构
CN105209621B (zh) * 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
ES2887254T3 (es) 2013-03-08 2021-12-22 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
ES2749624T3 (es) 2013-03-14 2020-03-23 Caribou Biosciences Inc Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico
US10378026B2 (en) * 2013-09-02 2019-08-13 Cellectis RNA based method to obtain stably integrated retroviral vectors
CN111218447B (zh) 2013-11-07 2024-10-11 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US9663770B2 (en) 2014-01-22 2017-05-30 Life Technologies Corporation Reverse transcriptases for use in high temperature nucleic acid synthesis
CN113930455A (zh) 2014-10-09 2022-01-14 生命技术公司 Crispr寡核苷酸和基因剪辑
DK3386484T3 (da) 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
WO2017132580A2 (en) 2016-01-29 2017-08-03 The Trustees Of Princeton University Split inteins with exceptional splicing activity
EP3417062B1 (en) 2016-02-15 2024-06-26 Temple University - Of The Commonwealth System of Higher Education Excision of retroviral nucleic acid sequences
ES3030658T3 (en) 2016-03-30 2025-07-01 Intellia Therapeutics Inc Lipid nanoparticle formulations for crispr/cas components
US11427838B2 (en) 2016-06-29 2022-08-30 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
WO2018045321A1 (en) 2016-09-02 2018-03-08 North Carolina State University Methods and compositions for modification of plastid genomes
WO2018049075A1 (en) 2016-09-07 2018-03-15 Flagship Pioneering, Inc. Methods and compositions for modulating gene expression
US11280790B2 (en) 2016-10-04 2022-03-22 Svar Life Science Ab System and products for improved quantification of ADCC activity
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
US20190330620A1 (en) 2016-10-14 2019-10-31 Emendobio Inc. Rna compositions for genome editing
US20180127759A1 (en) 2016-10-28 2018-05-10 Massachusetts Institute Of Technology Dynamic genome engineering
WO2018089860A1 (en) 2016-11-11 2018-05-17 2D Genomics Inc. Methods for processing nucleic acid samples
US9816093B1 (en) 2016-12-06 2017-11-14 Caribou Biosciences, Inc. Engineered nucleic acid-targeting nucleic acids
EP3551757A1 (en) 2016-12-08 2019-10-16 Intellia Therapeutics, Inc. Modified guide rnas
EP3596217A1 (en) 2017-03-14 2020-01-22 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
WO2019005955A1 (en) 2017-06-27 2019-01-03 Yale University ENHANCED REVERSE TRANSCRIPTASE AND METHODS OF USE THEREOF
WO2019040650A1 (en) 2017-08-23 2019-02-28 The General Hospital Corporation GENETICALLY MODIFIED CRISPR-CAS9 NUCLEASES HAVING MODIFIED PAM SPECIFICITY
CN111315889A (zh) 2017-09-08 2020-06-19 生命技术公司 提高同源重组的方法和其组合物
EP3688162B1 (en) 2017-09-29 2024-03-06 Intellia Therapeutics, Inc. Formulations
IL311278B2 (en) 2017-09-29 2026-05-01 Intellia Therapeutics Inc Polynucleotides, compositions, and methods for genome editing
WO2019070843A1 (en) 2017-10-03 2019-04-11 Board Of Regents, The University Of Texas System INVERSE TRANSCRIPTASE WITH LTR-FREE BACKLIGHTS AND USES THEREOF
JP2021505159A (ja) 2017-12-06 2021-02-18 ジェネレーション バイオ カンパニー 修飾型閉端dna(cedna)を使用する遺伝子編集
CA3084825A1 (en) 2017-12-14 2019-06-20 Crispr Therapeutics Ag Novel rna-programmable endonuclease systems and their use in genome editing and other applications
US11293019B2 (en) 2017-12-22 2022-04-05 Gflas Life Sciences, Inc. Chimeric genome engineering molecules and methods
CA3092459A1 (en) 2018-03-02 2019-09-06 Generation Bio Co. Closed-ended dna (cedna) vectors for insertion of transgenes at genomic safe harbors (gsh) in humans and murine genomes
DK3765616T3 (da) 2018-03-14 2023-08-21 Arbor Biotechnologies Inc Nye enzymer og systemer målrettet crispr dna og rna
US11339385B2 (en) 2018-03-25 2022-05-24 GeneTether, Inc. Modified nucleic acid editing systems for tethering donor DNA
CA3104989A1 (en) 2018-03-27 2019-10-03 G+Flas Life Sciences Sequence-specific in vivo cell targeting
CA3105953A1 (en) 2018-07-09 2020-01-16 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
WO2020033083A1 (en) 2018-08-10 2020-02-13 Cornell University Optimized base editors enable efficient editing in cells, organoids and mice
AU2019327449B2 (en) 2018-08-28 2026-04-09 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
KR20210055733A (ko) 2018-09-07 2021-05-17 빔 테라퓨틱스, 인크. 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
WO2020068897A1 (en) 2018-09-25 2020-04-02 Massachusetts Institute Of Technology Engineered dcas9 with reduced toxicity and its use in genetic circuits
CA3121191A1 (en) 2018-11-28 2020-06-04 Crispr Therapeutics Ag Optimized mrna encoding cas9 for use in lnps
JP7646552B2 (ja) 2019-01-31 2025-03-17 ビーム セラピューティクス インク. 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ
SG11202108812SA (en) * 2019-02-15 2021-09-29 Sigma Aldrich Co Llc Crispr/cas fusion proteins and systems
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020241869A1 (ja) * 2019-05-30 2020-12-03 国立大学法人東京大学 2種の核酸塩基変換酵素が融合されたCasタンパク質を利用したゲノム編集システム
US20220298495A1 (en) 2019-06-12 2022-09-22 Emendobio Inc. Novel genome editing tool
CA3147875A1 (en) 2019-07-19 2021-01-28 Flagship Pioneering Innovations Vi, Llc Recombinase compositions and methods of use
WO2021042047A1 (en) 2019-08-30 2021-03-04 The General Hospital Corporation C-to-g transversion dna base editors
EP4034659A4 (en) 2019-09-27 2024-10-16 The Broad Institute, Inc. PROGRAMMABLE POLYNUCLEOTIDE EDITORS FOR AMPLIFIED HOMOLOGOUS RECOMBINATION
WO2021080922A1 (en) * 2019-10-21 2021-04-29 The Trustees Of Columbia University In The City Of New York Methods of performing rna templated genome editing
JP7785002B2 (ja) * 2019-11-05 2025-12-12 ペアーワイズ プランツ サービシズ, インコーポレイテッド 対立遺伝子のrnaにコードされたdnaの置換のための組成物および方法
EP4061940A4 (en) 2019-11-22 2024-10-23 Flagship Pioneering Innovations VI, LLC RECOMBINASE COMPOSITIONS AND METHODS OF USE
US20230051661A1 (en) 2019-12-26 2023-02-16 Agency For Science, Technology And Research Nucleobase Editors
WO2021138469A1 (en) * 2019-12-30 2021-07-08 The Broad Institute, Inc. Genome editing using reverse transcriptase enabled and fully active crispr complexes
BR112022017715A2 (pt) 2020-03-04 2022-11-16 Flagship Pioneering Innovations Vi Llc Métodos e composições para modular um genoma
AU2021232005A1 (en) 2020-03-04 2022-09-29 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
IL296095A (en) 2020-03-04 2022-11-01 Flagship Pioneering Innovations Vi Llc Improved methods and compositions for genome modulation
US20230348939A1 (en) 2020-03-04 2023-11-02 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
BR112022017735A2 (pt) 2020-03-05 2022-11-29 Flagship Pioneering Innovations Vi Llc Métodos e composições de supressão de defesa de hospedeiro para modular um genoma
WO2021188840A1 (en) 2020-03-19 2021-09-23 Rewrite Therapeutics, Inc. Methods and compositions for directed genome editing
CN115427566A (zh) 2020-04-08 2022-12-02 阿斯利康(瑞典)有限公司 用于改善的位点特异性修饰的组合物和方法
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
WO2021248102A1 (en) 2020-06-05 2021-12-09 Flagship Pioneering Innovations Vi, Llc Template guide rna molecules
AU2021403660A1 (en) 2020-12-16 2023-07-06 Universitat Pompeu Fabra Programmable transposases and uses thereof
AU2022206476A1 (en) 2021-01-11 2023-07-20 President And Fellows Of Harvard College Prime editor variants, constructs, and methods for enhancing prime editing efficiency and precision
CN116745428A (zh) 2021-01-14 2023-09-12 加利福尼亚大学董事会 位点特异性基因修饰
WO2022155532A1 (en) 2021-01-15 2022-07-21 4M Genomics Inc. Polypeptide fusions or conjugates for gene editing
KR102876548B1 (ko) 2021-01-21 2025-10-30 한국생명공학연구원 Francisella novicida Cas9 모듈 기반의 역전사 효소를 사용한 유전체 치환 및 삽입 기술
US20230374476A1 (en) 2021-02-05 2023-11-23 University Of Massachusetts Prime editor system for in vivo genome editing
US20240132916A1 (en) 2021-02-09 2024-04-25 The Broad Institute, Inc. Nuclease-guided non-ltr retrotransposons and uses thereof
WO2022183210A1 (en) 2021-02-26 2022-09-01 Flagship Pioneering Innovations Vi, Llc Tissue-specific methods and compositions for modulating a genome
EP4314257A4 (en) 2021-04-01 2025-07-09 Prime Medicine Inc METHODS AND COMPOSITIONS FOR EDITING NUCLEOTIDE SEQUENCES
EP4352230A4 (en) 2021-06-03 2025-06-11 Prime Medicine, Inc. Genome editing compositions and methods for treating Wilson's disease
WO2023283092A1 (en) 2021-07-06 2023-01-12 Prime Medicine, Inc. Compositions and methods for efficient genome editing
WO2023004439A2 (en) 2021-07-23 2023-01-26 Prime Medicine, Inc. Genome editing compositions and methods for treatment of chronic granulomatous disease
WO2023015318A2 (en) 2021-08-05 2023-02-09 Prime Medicine, Inc. Genome editing compositions and methods for treatment of cystic fibrosis
US20240360476A1 (en) 2021-08-05 2024-10-31 Prime Medicine, Inc. Genome Editing Compositions and Methods for Treatment of Myotonic Dystrophy
AU2022325166A1 (en) 2021-08-06 2024-02-08 President And Fellows Of Harvard College Improved prime editors and methods of use
WO2023039447A2 (en) 2021-09-08 2023-03-16 Flagship Pioneering Innovations Vi, Llc Serpina-modulating compositions and methods
CA3231712A1 (en) 2021-09-08 2023-03-16 Flagship Pioneering Innovations Vi, Llc Pah-modulating compositions and methods
KR20260037664A (ko) 2021-09-08 2026-03-18 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 게놈을 조절하기 위한 방법 및 조성물
WO2023039586A1 (en) 2021-09-10 2023-03-16 Agilent Technologies, Inc. Guide rnas with chemical modification for prime editing
US20240425831A1 (en) 2021-10-08 2024-12-26 The General Hospital Corporation Improved crispr prime editors
CA3235826A1 (en) 2021-10-21 2023-04-27 Wei Hsi Yeh Genome editing compositions and methods for treatment of usher syndrome type 3
US20250011766A1 (en) 2021-11-09 2025-01-09 Prime Medicine, Inc. Genome Editing Compositions and Methods for Treatment of Amyotrophic Lateral Sclerosis
US20250319202A1 (en) 2021-11-09 2025-10-16 Prime Medicine, Inc. Genome editing compositions and methods for treatment of fuchs endothelial corneal dystrophy
EP4430189A1 (en) 2021-11-11 2024-09-18 Prime Medicine, Inc. Genome editing compositions and methods for treatment of fragile x syndrome
US20250297248A1 (en) 2021-11-24 2025-09-25 Prime Medicine, Inc. Methods and compositions for inhibiting mismatch repair
AU2022398241A1 (en) 2021-11-24 2024-06-06 Prime Medicine, Inc. Modified prime editing guide rnas
EP4444362A4 (en) 2021-12-10 2026-04-01 Flagship Pioneering Innovations Vi Llc CFTR COMPOSITIONS AND MODULATION METHODS
WO2023192655A2 (en) 2022-04-01 2023-10-05 Prime Medicine, Inc. Methods and compositions for editing nucleotide sequences
CA3260587A1 (en) * 2022-06-24 2023-12-28 Flagship Pioneering Innovations Vi, Llc FAH COMPOSITIONS AND MODULATION METHODS

Also Published As

Publication number Publication date
US20240002822A1 (en) 2024-01-04
EP4399292A2 (en) 2024-07-17
US20240026324A1 (en) 2024-01-25
IL311225A (en) 2024-05-01
US20240076638A1 (en) 2024-03-07
KR20260037664A (ko) 2026-03-18
CA3231677A1 (en) 2023-03-16
MX2024002927A (es) 2024-05-29
EP4399292A4 (en) 2025-11-12
US20240247243A1 (en) 2024-07-25
US12037617B2 (en) 2024-07-16
US12123034B2 (en) 2024-10-22
JP2024533311A (ja) 2024-09-12
AU2022343268A1 (en) 2024-03-28
WO2023039424A2 (en) 2023-03-16
US12031162B2 (en) 2024-07-09
US12024728B2 (en) 2024-07-02
WO2023039424A3 (en) 2023-07-06
US20240002886A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
US12024728B2 (en) Methods and compositions for modulating a genome
TW202323524A (zh) Hbb—調節組合物及方法
US12270029B2 (en) CFTR-modulating compositions and methods
JP2024533312A (ja) Serpina調節組成物及び方法
TW202320810A (zh) Pah調節組合物及方法
IL311219A (en) Methods and compositions for genome modulation
WO2023250492A2 (en) Fah-modulating compositions and methods
US20260132425A1 (en) Improved gene editing systems utilizing trans recruiting components
US20250305002A1 (en) Recruitment in trans of gene editing system components
TW202444915A (zh) Serpina調節組合物及方法
TW202440138A (zh) Pah調節系統及方法
WO2025235506A2 (en) Atp7b-modulating compositions and methods
CN118489007A (zh) 调节基因组的方法和组合物
WO2023225471A2 (en) Helitron compositions and methods
CN118556123A (zh) Hbb调节性组合物和方法
CN118613588A (zh) Serpina调节组合物和方法